Innate Pharma (NASDAQ:IPHA) Lowered to Neutral Rating by HC Wainwright

Key Points

• HC Wainwright has reaffirmed its neutral rating for Innate Pharma with little change to their outlook.
• Leerink Partners has downgraded its price target for the stock to $2.00, down from $10.00, indicating a market perform rating.
• Innate Pharma's stock price is currently around $2.05 with a 52-week low of $1.29 and high of $3.51.

Innate Pharma (NASDAQ:IPHA - Get Free Report) was downgraded by HC Wainwright from a "buy" rating to a "neutral" rating in a report issued on Thursday, MarketBeat.com reports.

A number of other equities research analysts also recently issued reports on IPHA. Leerink Partners reiterated a "market perform" rating and issued a $2.00 price objective (down previously from $10.00) on shares of Innate Pharma in a research report on Thursday. BTIG Research initiated coverage on Innate Pharma in a research report on Monday, July 28th. They set a "buy" rating on the stock. One investment analyst has rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, Innate Pharma presently has a consensus rating of "Hold" and an average price target of $6.50.

Innate Pharma Stock Down 3.9%

Shares of IPHA stock traded down $0.08 on Thursday, reaching $1.97. The company's stock had a trading volume of 4,451 shares, compared to its average volume of 94,337. The company has a current ratio of 2.60, a quick ratio of 2.60 and a debt-to-equity ratio of 2.52. Innate Pharma has a 12-month low of $1.29 and a 12-month high of $3.51. The stock's 50 day simple moving average is $2.06 and its 200-day simple moving average is $2.02.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.